We are live on ! Find out more
NEOS

Neos Therapeutics, Inc
NEOS

Delisted

NEOS was delisted on the 19th of March, 2021.

Back to rankings

51 hedge funds and large institutions have $30.4M invested in Neos Therapeutics, Inc in 2019 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 18 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

3% more capital invested

Capital invested by funds: $29.4M → $30.4M (+$981K)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

12% less funds holding

Funds holding: 58 → 51 (-7)

44% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 18

54% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 13

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $7K

Holders
51
Holders Change
-7
Holders Change %
-12.07%
% of All Funds
1.12%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
6
Increased
10
Reduced
18
Closed
13
Calls
–
Puts
$7K
Net Calls
-$7K
Net Calls Change
-$8K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$431K
2
SFM
Sphera Funds Management
Israel
+$319K
3
WG
Winton Group
United Kingdom
+$144K
4
BCM
Bridgeway Capital Management
Texas
+$113K
5
OAM
Oxford Asset Management
United Kingdom
+$81.3K

Top Sellers

Rank Fund Capital Flow
1
SCM
Stonepine Capital Management
Oregon
-$759K
2
Morgan Stanley
Morgan Stanley
New York
-$674K
3
Millennium Management
Millennium Management
New York
-$654K
4
Northern Trust
Northern Trust
Illinois
-$629K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$387K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
26
Southport Capital Management
Tennessee
$36K – – –
ARTA
27
A.R.T. Advisors
New York
$35K +$38.1K +23,524 New
ACM
28
Allred Capital Management
Texas
$34K – – –
Charles Schwab
29
Charles Schwab
California
$32K – – –
D.E. Shaw & Co
30
D.E. Shaw & Co
New York
$28K -$40.9K -25,253 -58%
CIBC Private Wealth Group
31
CIBC Private Wealth Group
Georgia
$23K – – –
LP
32
LMR Partners
United Kingdom
$22K – – –
Bank of New York Mellon
33
Bank of New York Mellon
New York
$20K – – –
TRCT
34
Tower Research Capital (TRC)
New York
$20K +$13K +8,062 +147%
AG
35
Advisor Group
Arizona
$19K – – –
Commonwealth Equity Services
36
Commonwealth Equity Services
Massachusetts
$17K +$18.8K +11,600 New
RJA
37
Raymond James & Associates
Florida
$16K – – –
SCA
38
Stonebridge Capital Advisors
Minnesota
$15K +$16.2K +10,000 New
Victory Capital Management
39
Victory Capital Management
Texas
$13K +$13.8K +8,503 New
Royal Bank of Canada
40
Royal Bank of Canada
Ontario, Canada
$12K -$7.28K -4,500 -36%
MAM
41
Meeder Asset Management
Ohio
$11K +$9.09K +5,616 +288%
BNP Paribas Financial Markets
42
BNP Paribas Financial Markets
France
$8.18K – – –
JP Morgan Chase
43
JP Morgan Chase
New York
$7K -$341K -211,006 -98%
Group One Trading
44
Group One Trading
Illinois
$7K +$4.05K +2,500 +125%
UBS Group
45
UBS Group
Switzerland
$3K +$2.83K +1,750 +694%
Morgan Stanley
46
Morgan Stanley
New York
$2K -$674K -416,552 -100%
Bank of America
47
Bank of America
North Carolina
$2K -$55.6K -34,376 -97%
LTFS
48
Ladenburg Thalmann Financial Services
Florida
$1K – – –
Rockefeller Capital Management
49
Rockefeller Capital Management
New York
$1K +$935 +578 New
Jane Street
50
Jane Street
New York
– -$213K -165,503 Closed
1
2
3

NEOS Hedge Fund Activity: Q3 2019 in Review

51 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Neos Therapeutics, Inc (NEOS) for Q3 2019, worth a combined $30.4M — up 3.3% from $29.4M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of NEOS and 6 opened new positions — a net loss of 7 holders — while 18 trimmed existing stakes and 10 added.

The largest buyer was Renaissance Technologies, adding an estimated $431K. The largest seller was Stonepine Capital Management, cutting an estimated $759K.

  • 51 institutional investors held Neos Therapeutics, Inc (NEOS) as of Q3 2019, down from 58 in Q2 2019.
  • Funds reported $30.4M of Neos Therapeutics, Inc stock for Q3 2019, up 3.3% quarter-over-quarter.
  • 6 funds opened new Neos Therapeutics, Inc positions in Q3 2019 and 13 closed out, a net change of -7 holders.
  • The largest Neos Therapeutics, Inc buyer in Q3 2019 was Renaissance Technologies, an estimated $431K added.
  • The largest Neos Therapeutics, Inc seller in Q3 2019 was Stonepine Capital Management, an estimated $759K sold.

Based on aggregated 13F filings for Q3 2019.